IP Library › Granted Patent US 12,466,889
Granted Patent B2
US 12,466,889 · App. 18/047,605 · Granted Nov 11, 2025

Anti-HLA-G antibodies and use thereof

Inventors: Alexander Bujotzek (Munich, DE); Alejandro Carpy Gutierrez Cirlos (Munich, DE); Anne Freimoser-Grundschober (Zurich, CH); Carina Hage (Penzberg, DE); Thomas Hofer (Zurich, CH); Silke Kirchner (Penzberg, DE); Meher Majety (Munich, DE); Ekkehard Moessner (Kreuzlingen, CH); Christiane Neumann (Schlieren, CH); Christian Spick (Seeshaupt, DE); Georg Tiefenthaler (Sindelsdorf, DE); Thomas Weindl (Lenggries, DE)
Assignee: Hoffmann-La Roche Inc.
C07K16/2833A61P35/00C07K2317/31C07K2317/52C07K2317/56C07K2317/565
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,466,889
App. No.
18/047,605
Granted
Nov 11, 2025
Kind
B2
Abstract

The present invention relates to antibodies that bind to human HLA-G, multispecific antibodies thereof, their preparation, formulations, and methods of using the same.

Claims (201)

1 . A bispecific antibody that binds to human HLA-G and human CD3, comprising:

a first antigen binding moiety that binds to human HLA-G and comprises:

A) (a) a heavy chain variable (VH) domain comprising (i) heavy chain complementarity determining region (CDR) 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO:1, (ii) heavy chain CDR 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:2, and (iii) heavy chain CDR 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:3; and (b) a light chain variable (VL) domain comprising (i) light chain CDR 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:23, (ii) light chain CDR 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:5, and (iii) light chain CDR 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6; or

B) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:25, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; and

a second antigen binding moiety that binds to human CD3 and comprises:

C) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:52, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:53, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:54; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:55, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:56, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:57;

D) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:60, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:61, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:62; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:63, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:64, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:65; or

E) (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:68, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:69, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:70; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:71, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:72, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:73.

2 . A bispecific antibody that binds to human HLA-G and human CD3, comprising:

a first antigen binding moiety that binds to human HLA-G and comprises (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6; and

a second antigen binding moiety that binds to human CD3 and comprises (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:52, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:53, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:54; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:55, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:56, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO: 57.

3 . The bispecific antibody of claim 1 ,

wherein the first antigen binding moiety comprises:

A) a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:24; or

B) a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:26, and wherein the second antigen binding moiety comprises:

C) a VH domain comprising the amino acid sequence of SEQ ID NO:58 and a VL domain comprising the amino acid sequence of SEQ ID NO:59;

D) a VH domain comprising the amino acid sequence of SEQ ID NO:66 and a VL domain comprising the amino acid sequence of SEQ ID NO:67; or

E) a VH domain comprising the amino acid sequence of SEQ ID NO:74 and a VL domain comprising the amino acid sequence of SEQ ID NO:75.

4 . A bispecific antibody that binds to human HLA-G and human CD3, comprising:

a first antigen binding moiety that binds to human HLA-G and comprises a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:24; and

a second antigen binding moiety that binds to human CD3 and comprises a VH domain comprising the amino acid sequence of SEQ ID NO:58 and a VL domain comprising the amino acid sequence of SEQ ID NO:59.

5 . The bispecific antibody of claim 1 , wherein the bispecific antibody shows:

a) inhibition of ILT2 or ILT4 binding to HLA-G;

b) antibody-mediated IFN gamma secretion by T cells on

i) SKOV3 cells transfected with recombinant HLA-G; or

ii) JEG3 cells expressing endogenous HLA-G;

c) T cell-mediated cytotoxicity or tumor cell killing on

i) SKOV3 cells transfected with recombinant HLA-G; or

ii) JEG3 cells expressing endogenous HLA-G;

d) in vivo anti-tumor efficacy or tumor regression in humanized NSG mice bearing SKOV3 human ovarian carcinoma transfected with recombinant HLA-G; or

e) in vivo anti-tumor efficacy or tumor regression in humanized NSG mice bearing human breast cancer patient-derived xenograft BC004 tumors.

6 . One or more isolated nucleic acids encoding the bispecific antibody of claim 1 .

7 . A host cell comprising the one or more nucleic acids of claim 6 .

8 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 7 , comprising culturing the host cell so that the bispecific antibody is produced.

9 . The method of claim 8 , further comprising recovering the bispecific antibody from the host cell.

10 . A pharmaceutical formulation comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

11 . The bispecific antibody of claim 2 , further comprising a third antigen binding moiety that binds to human HLA-G and comprises (a) a VH domain comprising (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3; and (b) a VL domain comprising (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:23, (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.

12 . The bispecific antibody of claim 11 , wherein the first, the second, and the third antigen binding moieties are each a Fab molecule; wherein each of the three Fab molecules comprises a light chain constant domain (CL) and a heavy chain constant domain 1 (CH1); and wherein the bispecific antibody further comprises an Fc domain comprising a first Fc subunit and a second Fc subunit.

13 . The bispecific antibody of claim 12 , wherein:

a) the first and the third Fab molecules are each a conventional Fab molecule; and

b) the second Fab molecule is a crossover Fab molecule.

14 . The bispecific antibody of claim 13 , wherein:

a) the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule, and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and

b) the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

15 . The bispecific antibody of claim 14 , wherein:

a) in the CL of the first and the third Fab molecules,

i) the amino acid at position 123 is substituted by lysine (K), arginine (R), or histidine (H); and

ii) the amino acid at position 124 is substituted by lysine (K), arginine (R), or histidine (H),

wherein the amino acid positions are numbered according to Kabat, and

b) in the CH1 of the first and the third Fab molecules,

iii) the amino acid at position 147 is substituted by glutamic acid (E) or aspartic acid (D); and

iv) the amino acid at position 213 is substituted by glutamic acid (E) or aspartic acid (D),

wherein the amino acid positions are numbered according to the Kabat EU index.

16 . The bispecific antibody of claim 15 , wherein:

a) in the CL of the first and the third Fab molecules,

i) the amino acid at position 123 is substituted by arginine (R); and

ii) the amino acid at position 124 is substituted by lysine (K),

wherein the amino acid positions are numbered according to Kabat, and

b) in the CH1 of the first and the third Fab molecules,

iii) the amino acid at position 147 is substituted by glutamic acid (E); and

iv) the amino acid at position 213 is substituted by glutamic acid (E),

wherein the amino acid positions are numbered according to the Kabat EU index.

17 . The bispecific antibody of claim 16 , wherein:

a) in the first subunit of the Fc domain, the amino acid at position 366 is substituted by tryptophan (W); and

b) in the second subunit of the Fc domain, the amino acid at position 366 is substituted by serine(S), the amino acid at position 368 is substituted by alanine (A), and the amino acid at position 407 is substituted by valine (V),

wherein the amino acid positions are numbered according to the Kabat EU index.

18 . The bispecific antibody of claim 17 , wherein the Fc domain is of the IgG1 isotype.

19 . The bispecific antibody of claim 18 , wherein in each of the first and the second subunits of the Fc domain:

the amino acid at position 234 is substituted by alanine (A);

the amino acid at position 235 is substituted by alanine (A); and

the amino acid at position 329 is substituted by glycine (G),

wherein the amino acid positions are numbered according to the Kabat EU index.

20 . The bispecific antibody of claim 12 , wherein the first and the third Fab molecules each comprises a VH domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7 and a VL domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24; and

wherein the second Fab molecule comprises a VH domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:58 and a VL domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:59.

21 . The bispecific antibody of claim 19 , wherein the first and the third Fab molecules each comprises a VH domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:7 and a VL domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO: 24; and

wherein the second Fab molecule comprises a VH domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:58 and a VL domain comprising an amino acid sequence of at least 95% sequence identity to the amino acid sequence of SEQ ID NO:59.

22 . The bispecific antibody of claim 11 , wherein the bispecific antibody comprises:

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 76;

two polypeptides comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 77;

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 78; and

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 79.

23 . The bispecific antibody of claim 19 , wherein the bispecific antibody comprises:

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 76;

two polypeptides comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 77;

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 78; and

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 79.

24 . A pharmaceutical formulation comprising the bispecific antibody of claim 11 and a pharmaceutically acceptable carrier.

25 . A pharmaceutical formulation comprising the bispecific antibody of claim 19 and a pharmaceutically acceptable carrier.

26 . A pharmaceutical formulation comprising the bispecific antibody of claim 20 and a pharmaceutically acceptable carrier.

27 . A pharmaceutical formulation comprising the bispecific antibody of claim 21 and a pharmaceutically acceptable carrier.

28 . A pharmaceutical formulation comprising the bispecific antibody of claim 22 and a pharmaceutically acceptable carrier.

29 . A pharmaceutical formulation comprising the bispecific antibody of claim 23 and a pharmaceutically acceptable carrier.

30 . The bispecific antibody of claim 4 , further comprising a third antigen binding moiety that binds to human HLA-G and comprises a VH domain comprising the amino acid sequence of SEQ ID NO:7 and a VL domain comprising the amino acid sequence of SEQ ID NO:24.

31 . The bispecific antibody of claim 30 , wherein the first, the second, and the third antigen binding moieties are each a Fab molecule; wherein each of the three Fab molecules comprises a CL and a CH1; and wherein the bispecific antibody further comprises an Fc domain comprising a first Fc subunit and a second Fc subunit.

32 . The bispecific antibody of claim 31 , wherein:

a) the first and the third Fab molecules are each a conventional Fab molecule; and

b) the second Fab molecule is a crossover Fab molecule.

33 . The bispecific antibody of claim 32 , wherein:

a) the first Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second Fab molecule and the second Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first subunit of the Fc domain; and

b) the third Fab molecule is fused at the C-terminus of the Fab heavy chain to the N-terminus of the second subunit of the Fc domain.

34 . The bispecific antibody of claim 33 , wherein:

a) in the CL of the first and the third Fab molecules,

i) the amino acid at position 123 is substituted by lysine (K), arginine (R), or histidine (H); and

ii) the amino acid at position 124 is substituted by lysine (K), arginine (R), or histidine (H),

wherein the amino acid positions are numbered according to Kabat, and

b) in the CH1 of the first and the third Fab molecules,

iii) the amino acid at position 147 is substituted by glutamic acid (E) or aspartic acid (D); and

iv) the amino acid at position 213 is substituted by glutamic acid (E) or aspartic acid (D),

wherein the amino acid positions are numbered according to the Kabat EU index.

35 . The bispecific antibody of claim 34 , wherein:

a) in the CL of the first and the third Fab molecules,

i) the amino acid at position 123 is substituted by arginine (R); and

ii) the amino acid at position 124 is substituted by lysine (K),

wherein the amino acid positions are numbered according to Kabat, and

b) in the CH1 of the first and the third Fab molecules,

iii) the amino acid at position 147 is substituted by glutamic acid (E); and

iv) the amino acid at position 213 is substituted by glutamic acid (E),

wherein the amino acid positions are numbered according to the Kabat EU index.

36 . The bispecific antibody of claim 35 , wherein:

a) in the first subunit of the Fc domain, the amino acid at position 366 is substituted by tryptophan (W); and

b) in the second subunit of the Fc domain, the amino acid at position 366 is substituted by serine(S), the amino acid at position 368 is substituted by alanine (A), and the amino acid at position 407 is substituted by valine (V),

wherein the amino acid positions are numbered according to the Kabat EU index.

37 . The bispecific antibody of claim 36 , wherein the Fc domain is of the IgG1 isotype.

38 . The bispecific antibody of claim 37 , wherein in each of the first and the second subunits of the Fc domain:

the amino acid at position 234 is substituted by alanine (A);

the amino acid at position 235 is substituted by alanine (A); and

the amino acid at position 329 is substituted by glycine (G),

wherein the amino acid positions are numbered according to the Kabat EU index.

39 . A bispecific antibody that binds to human HLA-G and human CD3, wherein the bispecific antibody comprises:

a VH domain that binds to human CD3 comprising the amino acid sequence of SEQ ID NO: 58 and a VL domain that binds to human CD3 comprising the amino acid sequence of SEQ ID NO: 59, and

two VH domains that bind to human HLA-G comprising SEQ ID NO: 7 and two VL domains that bind to human HLA-G comprising SEQ ID NO: 24, wherein the bispecific antibody comprises

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 76, wherein the polypeptide comprises, in an N- to C-terminal direction, the VH domain comprising the amino acid sequence of SEQ ID NO: 58 and a CL domain;

two polypeptides comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 77, wherein each of the two polypeptides comprises, in an N- to C-terminal direction, one of the two VL domains comprising the amino acid sequence of SEQ ID NO: 24 and a CL domain;

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 78, wherein the polypeptide comprises, in an N- to C-terminal direction, one of the two VH domains comprising the amino acid sequence of SEQ ID NO: 7 and a CH1 domain; and

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 79, wherein the polypeptide comprises, in an N- to C-terminal direction, one of the two VH domains comprising the amino acid sequence of SEQ ID NO: 7, a CH1 domain, the VL domain comprising the amino acid sequence of SEQ ID NO: 59, and a CH1 domain.

40 . A bispecific antibody that binds to human HLA-G and human CD3, wherein the bispecific antibody comprises:

a VH domain that binds to human CD3 comprising the amino acid sequence of SEQ ID NO: 58 and a VL domain that binds to human CD3 comprising the amino acid sequence of SEQ ID NO: 59, and

two VH domains that bind to human HLA-G comprising SEQ ID NO: 7 and two VL domains that bind to human HLA-G comprising SEQ ID NO: 24, wherein the bispecific antibody comprises

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 76, wherein the polypeptide comprises, in an N- to C-terminal direction, the VH domain comprising the amino acid sequence of SEQ ID NO: 58 and a CL domain;

two polypeptides comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 77, wherein each of the polypeptides chains comprises, in an N- to C-terminal direction, one of the two VL domains comprising the amino acid sequence of SEQ ID NO: 24 and a CL domain, and wherein, in the CL, (i) the amino acid at position 123 is substituted by arginine (R); and (ii) the amino acid at position 124 is substituted by lysine (K), wherein the amino acid positions are numbered according to Kabat;

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 78, wherein the polypeptide comprises an N- to C-terminal direction, one of the two VH domains comprising the amino acid sequence of SEQ ID NO: 7, a CH1 domain, a CH2 domain and a CH3 domain; wherein, in the CH1 domain, (i) the amino acid at position 147 is substituted by glutamic acid (E); and (ii) the amino acid at position 213 is substituted by glutamic acid (E), wherein the amino acid positions are numbered according to the Kabat EU index; wherein, in the CH3 domain, the amino acid at position 349 is substituted by cysteine (C), the amino acid at position 366 is substituted by serine(S), the amino acid at position 368 is substituted by alanine (A), the amino acid at position 407 is substituted by valine (V);

wherein in the CH2 domain, the amino acid at position 234 is substituted by alanine (A), the amino acid at position 235 is substituted by alanine (A), and the amino acid at position 329 is substituted by glycine (G), wherein the amino acid positions are numbered according to the Kabat EU index; and

a polypeptide comprising an amino acid sequence that is at least 98% identical to the sequence of SEQ ID NO: 79, wherein the polypeptide comprises in an N- to C-terminal direction, one of the two VH domains comprising the amino acid sequence of SEQ ID NO: 7, a first CH1 domain, the VL domain comprising the amino acid sequence of SEQ ID NO: 59, a second CH1 domain, a CH2 domain and a CH3 domain; wherein, in the first CH1 domain, (i) the amino acid at position 147 is substituted by glutamic acid (E); and (ii) the amino acid at position 213 is substituted by glutamic acid (E), wherein the amino acid positions are numbered according to the Kabat EU index; wherein, in the CH3 domain, the amino acid at position 354 is substituted by cysteine (C), the amino acid at position 366 is substituted by tryptophan (W); wherein, in the CH2 domain, the amino acid at position 234 is substituted by alanine (A), the amino acid at position 235 is substituted by alanine (A), and the amino acid at position 329 is substituted by glycine (G), wherein the amino acid positions are numbered according to the Kabat EU index.

41 . A pharmaceutical formulation comprising the bispecific antibody of claim 30 and a pharmaceutically acceptable carrier.

42 . A pharmaceutical formulation comprising the bispecific antibody of claim 38 and a pharmaceutically acceptable carrier.

43 . A pharmaceutical formulation comprising the bispecific antibody of claim 39 and a pharmaceutically acceptable carrier.

44 . A pharmaceutical formulation comprising the bispecific antibody of claim 40 and a pharmaceutically acceptable carrier.

45 . A bispecific antibody that binds to human HLA-G and human CD3, comprising:

A) a polypeptide comprising the amino acid sequence of SEQ ID NO: 76; two polypeptides each comprising the amino acid sequence of SEQ ID NO: 77; a polypeptide comprising the amino acid sequence of SEQ ID NO: 78; and a polypeptide comprising the amino acid sequence of SEQ ID NO: 79;

B) a polypeptide comprising the amino acid sequence of SEQ ID NO: 80; two polypeptides each comprising the amino acid sequence of SEQ ID NO: 81; a polypeptide comprising the amino acid sequence of SEQ ID NO: 82; and a polypeptide comprising the amino acid sequence of SEQ ID NO: 83; or

C) a polypeptide comprising the amino acid sequence of SEQ ID NO: 84; two polypeptides each comprising the amino acid sequence of SEQ ID NO: 85; a polypeptide comprising the amino acid sequence of SEQ ID NO: 86; and a polypeptide comprising the amino acid sequence of SEQ ID NO: 87.

46 . A bispecific antibody that binds to human HLA-G and human CD3, comprising:

a polypeptide comprising the amino acid sequence of SEQ ID NO: 76;

two polypeptides each comprising the amino acid sequence of SEQ ID NO: 77;

a polypeptide comprising the amino acid sequence of SEQ ID NO: 78; and

a polypeptide comprising the amino acid sequence of SEQ ID NO: 79.

47 . A pharmaceutical formulation comprising the bispecific antibody of claim 46 and a pharmaceutically acceptable carrier.

48 . One or more isolated nucleic acids encoding the bispecific antibody of claim 31 .

49 . One or more isolated nucleic acids encoding the bispecific antibody of claim 19 .

50 . One or more isolated nucleic acids encoding the bispecific antibody of claim 20 .

51 . One or more isolated nucleic acids encoding the bispecific antibody of claim 21 .

52 . One or more isolated nucleic acids encoding the bispecific antibody of claim 22 .

53 . One or more isolated nucleic acids encoding the bispecific antibody of claim 23 .

54 . One or more isolated nucleic acids encoding the bispecific antibody of claim 30 .

55 . One or more isolated nucleic acids encoding the bispecific antibody of claim 38 .

56 . One or more isolated nucleic acids encoding the bispecific antibody of claim 39 .

57 . One or more isolated nucleic acids encoding the bispecific antibody of claim 40 .

58 . One or more isolated nucleic acids encoding the bispecific antibody of claim 46 .

59 . A host cell comprising the one or more nucleic acids of claim 48 .

60 . A host cell comprising the one or more nucleic acids of claim 49 .

61 . A host cell comprising the one or more nucleic acids of claim 50 .

62 . A host cell comprising the one or more nucleic acids of claim 51 .

63 . A host cell comprising the one or more nucleic acids of claim 52 .

64 . A host cell comprising the one or more nucleic acids of claim 53 .

65 . A host cell comprising the one or more nucleic acids of claim 54 .

66 . A host cell comprising the one or more nucleic acids of claim 55 .

67 . A host cell comprising the one or more nucleic acids of claim 56 .

68 . A host cell comprising the one or more nucleic acids of claim 57 .

69 . A host cell comprising the one or more nucleic acids of claim 58 .

70 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 59 , comprising culturing the host cell so that the bispecific antibody is produced.

71 . The method of claim 70 , further comprising recovering the bispecific antibody from the host cell.

72 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 60 , comprising culturing the host cell so that the bispecific antibody is produced.

73 . The method of claim 72 , further comprising recovering the bispecific antibody from the host cell.

74 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 61 , comprising culturing the host cell so that the bispecific antibody is produced.

75 . The method of claim 74 , further comprising recovering the bispecific antibody from the host cell.

76 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 62 , comprising culturing the host cell so that the bispecific antibody is produced.

77 . The method of claim 76 , further comprising recovering the bispecific antibody from the host cell.

78 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 63 , comprising culturing the host cell so that the bispecific antibody is produced.

79 . The method of claim 78 , further comprising recovering the bispecific antibody from the host cell.

80 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 64 , comprising culturing the host cell so that the bispecific antibody is produced.

81 . The method of claim 80 , further comprising recovering the bispecific antibody from the host cell.

82 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 65 , comprising culturing the host cell so that the bispecific antibody is produced.

83 . The method of claim 82 , further comprising recovering the bispecific antibody from the host cell.

84 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 66 , comprising culturing the host cell so that the bispecific antibody is produced.

85 . The method of claim 84 , further comprising recovering the bispecific antibody from the host cell.

86 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 67 , comprising culturing the host cell so that the bispecific antibody is produced.

87 . The method of claim 86 , further comprising recovering the bispecific antibody from the host cell.

88 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 68 , comprising culturing the host cell so that the bispecific antibody is produced.

89 . The method of claim 88 , further comprising recovering the bispecific antibody from the host cell.

90 . A method of producing the bispecific antibody encoded by the one or more nucleic acids of the host cell of claim 69 , comprising culturing the host cell so that the bispecific antibody is produced.

91 . The method of claim 90 , further comprising recovering the bispecific antibody from the host cell.

Priority Claims (2)
EP 20214951 · Dec 17, 2020 · regional
EP 21203272 · Oct 18, 2021 · regional
Continuity (2)
Continuation 17644525 · Dec 15, 2021
Related Publication 20230159642A1 · May 25, 2023
References Cited (400)
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4816567A · Cabilly · 1989 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5416064A · Chari et al. · 1995 [cited by applicant]
US 5500362A · Robinson · 1996 [cited by applicant]
US 5591828A · Bosslet et al. · 1997 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5635483A · Pettit et al. · 1997 [cited by applicant]
US 5648237A · Carter · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5712374A · Kuntsmann et al. · 1998 [cited by applicant]
US 5714586A · Kunstmann et al. · 1998 [cited by applicant]
US 5731168A · Carter · 1998 [cited by applicant]
US 5739116A · Hamann et al. · 1998 [cited by applicant]
US 5750373A · Garrard et al. · 1998 [cited by applicant]
US 5767285A · Hamann et al. · 1998 [cited by applicant]
US 5770429A · Lonberg et al. · 1998 [cited by applicant]
US 5770701A · McGahren et al. · 1998 [cited by applicant]
US 5770710A · McGahren et al. · 1998 [cited by applicant]
US 5773001A · Hamann et al. · 1998 [cited by applicant]
US 5780588A · Pettit et al. · 1998 [cited by applicant]
US 5789199A · Joly et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5840523A · Simmons et al. · 1998 [cited by applicant]
US 5869046A · Presta et al. · 1999 [cited by applicant]
US 5877296A · Hamann et al. · 1999 [cited by applicant]
US 5959177A · Hein et al. · 1999 [cited by applicant]
US 6040498A · Stomp et al. · 2000 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6171586B1 · Lam et al. · 2001 [cited by applicant]
US 6248516B1 · Winter et al. · 2001 [cited by applicant]
US 6267958B1 · Andya et al. · 2001 [cited by applicant]
US 6417429B1 · Hein et al. · 2002 [cited by applicant]
US 6420548B1 · Vezina et al. · 2002 [cited by applicant]
US 6630579B2 · Chari et al. · 2003 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6982321B2 · Winter · 2006 [cited by applicant]
US 7041870B2 · Tomizuka et al. · 2006 [cited by applicant]
US 7087409B2 · Barbas, III et al. · 2006 [cited by applicant]
US 7125978B1 · Vezina et al. · 2006 [cited by applicant]
US 7189826B2 · Rodman · 2007 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7498298B2 · Doronina et al. · 2009 [cited by applicant]
US 7521541B2 · Eigenbrot et al. · 2009 [cited by applicant]
US 7527791B2 · Adams et al. · 2009 [cited by applicant]
US 7695936B2 · Carter et al. · 2010 [cited by applicant]
US 11591397B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11608376B2 · Georges et al. · 2023 [cited by applicant]
US 11672858B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 11780920B2 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 20030232051A1 · Long et al. · 2003 [cited by applicant]
US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]
US 20050079574A1 · Bond · 2005 [cited by applicant]
US 20050119455A1 · Fuh et al. · 2005 [cited by applicant]
US 20050163770A1 · Reiter · 2005 [cited by applicant]
US 20050260186A1 · Bookbinder et al. · 2005 [cited by applicant]
US 20050266000A1 · Bond et al. · 2005 [cited by applicant]
US 20060025576A1 · Miller · 2006 [cited by applicant]
US 20060104968A1 · Bookbinder et al. · 2006 [cited by applicant]
US 20070020703A1 · Menier et al. · 2007 [cited by applicant]
US 20070061900A1 · Murphy et al. · 2007 [cited by applicant]
US 20070071675A1 · Wu et al. · 2007 [cited by applicant]
US 20070117126A1 · Sidhu et al. · 2007 [cited by applicant]
US 20070160598A1 · Dennis et al. · 2007 [cited by applicant]
US 20070237764A1 · Birtalan et al. · 2007 [cited by applicant]
US 20070259403A1 · Miyagawa et al. · 2007 [cited by applicant]
US 20070292936A1 · Barthelemy et al. · 2007 [cited by applicant]
US 20080069820A1 · Fuh et al. · 2008 [cited by applicant]
US 20090002360A1 · Chen et al. · 2009 [cited by applicant]
US 20110142864A1 · Dengjel · 2011 [cited by applicant]
US 20140051834A1 · Hoffman et al. · 2014 [cited by applicant]
US 20170355756A1 · Julien · 2017 [cited by examiner]
US 20200102389A1 · Fischer et al. · 2020 [cited by applicant]
US 20200199234A1 · Georges et al. · 2020 [cited by applicant]
US 20200270347A1 · Freimoser-Grundschober et al. · 2020 [cited by applicant]
US 20210147553A1 · Dengl et al. · 2021 [cited by applicant]
US 20210147554A1 · Dengl et al. · 2021 [cited by applicant]
US 20210403562A1 · Freimoser-Grundschober et al. · 2021 [cited by applicant]
US 20220010014A1 · Freimoser-Grundschober et al. · 2022 [cited by applicant]
US 20220213199A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20220259318A1 · Bujotzek et al. · 2022 [cited by applicant]
US 20230277662A1 · Freimoser-Grundschober et al. · 2023 [cited by applicant]
US 20230416411A1 · Bruenker et al. · 2023 [cited by applicant]
US 20240042022A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
US 20240043535A1 · Amann et al. · 2024 [cited by applicant]
US 20240132590A1 · Freimoser-Grundschober et al. · 2024 [cited by applicant]
CN 1308675A · 2001 [cited by applicant]
CN 1718588A · 2006 [cited by applicant]
CN 101967191A · 2011 [cited by applicant]
CN 104203982A · 2014 [cited by applicant]
CN 106795221A · 2017 [cited by applicant]
EP 0404097B1 · 1996 [cited by applicant]
EP 0425235B1 · 1996 [cited by applicant]
EP 2264067A1 · 2010 [cited by applicant]
EP 1870459B1 · 2016 [cited by applicant]
JP 2016505556A · 2016 [cited by applicant]
JP 2019526599A · 2019 [cited by applicant]
JP 2020511112A · 2020 [cited by applicant]
RU 2635537C2 · 2017 [cited by applicant]
WO WO9301161A1 · 1993 [cited by applicant]
WO WO199308829A1 · 1993 [cited by applicant]
WO WO199316185A2 · 1993 [cited by applicant]
WO WO199316185A3 · 1993 [cited by applicant]
WO WO9411026A2 · 1994 [cited by applicant]
WO WO9411026A3 · 1994 [cited by applicant]
WO WO9429351A2 · 1994 [cited by applicant]
WO WO9429351A3 · 1994 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9850431A2 · 1998 [cited by applicant]
WO WO9850431A3 · 1999 [cited by applicant]
WO WO9942128A1 · 1999 [cited by applicant]
WO WO0003016A1 · 2000 [cited by applicant]
WO WO0177342A1 · 2001 [cited by applicant]
WO WO0222784A2 · 2002 [cited by applicant]
WO WO2004056312A2 · 2004 [cited by applicant]
WO WO2004106381A1 · 2004 [cited by applicant]
WO WO2005061547A2 · 2005 [cited by applicant]
WO WO2005100402A1 · 2005 [cited by applicant]
WO WO2006029879A2 · 2006 [cited by applicant]
WO WO2006044908A2 · 2006 [cited by applicant]
WO WO2006029879A3 · 2006 [cited by applicant]
WO WO2007042261A2 · 2007 [cited by applicant]
WO WO2007110205A2 · 2007 [cited by applicant]
WO WO2007147901A1 · 2007 [cited by applicant]
WO WO2008024715A2 · 2008 [cited by applicant]
WO WO2008068048A2 · 2008 [cited by examiner]
WO WO2008119567A2 · 2008 [cited by applicant]
WO WO2009080251A1 · 2009 [cited by applicant]
WO WO2009080252A1 · 2009 [cited by applicant]
WO WO2009080253A1 · 2009 [cited by applicant]
WO WO2009080254A1 · 2009 [cited by applicant]
WO WO2009089004A1 · 2009 [cited by applicant]
WO WO2010112193A1 · 2010 [cited by applicant]
WO WO2010115589A1 · 2010 [cited by applicant]
WO WO2010129304A2 · 2010 [cited by applicant]
WO WO2010136172A1 · 2010 [cited by applicant]
WO WO2010145792A1 · 2010 [cited by applicant]
WO WO2010145793A1 · 2010 [cited by applicant]
WO WO2010150233A2 · 2010 [cited by applicant]
WO WO2010150235A1 · 2010 [cited by applicant]
WO WO2010129304A3 · 2011 [cited by applicant]
WO WO2011034605A2 · 2011 [cited by applicant]
WO WO2011090754A1 · 2011 [cited by applicant]
WO WO2011090762A1 · 2011 [cited by applicant]
WO WO2011117330A1 · 2011 [cited by applicant]
WO WO2010115589A8 · 2011 [cited by applicant]
WO WO2010145792A8 · 2011 [cited by applicant]
WO WO2011143545A1 · 2011 [cited by applicant]
WO WO2012020006A2 · 2012 [cited by applicant]
WO WO2012025525A1 · 2012 [cited by applicant]
WO WO2012025530A1 · 2012 [cited by applicant]
WO WO2012041968A1 · 2012 [cited by applicant]
WO WO2012058768A1 · 2012 [cited by applicant]
WO WO2012058768A8 · 2012 [cited by applicant]
WO 2014023708A1 · 2013 [cited by applicant]
WO WO2013026831A1 · 2013 [cited by applicant]
WO WO2013026833A1 · 2013 [cited by applicant]
WO WO2013026835A1 · 2013 [cited by applicant]
WO WO2013026839A1 · 2013 [cited by applicant]
WO WO2013059885A2 · 2013 [cited by applicant]
WO WO2013096291A2 · 2013 [cited by applicant]
WO WO2013106586A2 · 2013 [cited by applicant]
WO WO2013120929A1 · 2013 [cited by applicant]
WO WO2013096291A3 · 2013 [cited by applicant]
WO WO2013157953A1 · 2013 [cited by applicant]
WO WO2013157954A1 · 2013 [cited by applicant]
WO WO2013164325A1 · 2013 [cited by applicant]
WO WO2013174873A1 · 2013 [cited by applicant]
WO WO2014072534A1 · 2014 [cited by applicant]
WO WO2014093396A1 · 2014 [cited by applicant]
WO WO2014131712A1 · 2014 [cited by applicant]
WO WO2015066379A2 · 2015 [cited by applicant]
WO WO2015095392A1 · 2015 [cited by applicant]
WO WO2015095539A1 · 2015 [cited by applicant]
WO WO2015150447A1 · 2015 [cited by applicant]
WO WO2016016299A1 · 2016 [cited by applicant]
WO WO2016020309A1 · 2016 [cited by applicant]
WO WO2016062734A1 · 2016 [cited by applicant]
WO WO2016094566A2 · 2016 [cited by applicant]
WO 2016139181A1 · 2016 [cited by applicant]
WO WO2016160622A2 · 2016 [cited by applicant]
WO WO2016172485A2 · 2016 [cited by applicant]
WO 2022055926A1 · 2017 [cited by applicant]
WO 03031376A1 · 2017 [cited by applicant]
WO WO2017060144A1 · 2017 [cited by applicant]
WO WO2017207775A1 · 2017 [cited by applicant]
WO WO2018048763A1 · 2018 [cited by applicant]
WO 2022174031A1 · 2018 [cited by applicant]
WO WO2019202040A1 · 2019 [cited by applicant]
WO WO2019202041A1 · 2019 [cited by applicant]
WO WO2020043899A1 · 2020 [cited by applicant]
WO WO2020127618A1 · 2020 [cited by applicant]
WO WO2021255138A1 · 2021 [cited by applicant]
WO WO2021255143A1 · 2021 [cited by applicant]
WO WO2021255146A1 · 2021 [cited by applicant]
WO WO2021255155A1 · 2021 [cited by applicant]
Chen et al., Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations. Embo J. Jun. 15, 1995;14(12):2784-94. (Year: 1995). [cited by examiner]
Edwards et al., The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS. J Mol Biol. Nov. 14, 2003;334(1):103-18. (Year: 2003). [cited by examiner]
Koenig et al., Mutational landscape of antibody variable domains reveals a switch modulating the interdomain conformational dynamics and antigen binding. PNAS Jan. 24, 2017 114 (4) E486-E495; first published Jan. 5, 201… [cited by examiner]
Kussie, Paul H., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity”, 1994, Journal of Immunology 152(1): pp. 146-152. (Year: 1994). [cited by examiner]
Lu et al., “Preparation of anti-HLA-G monoclonal antibody G11E5,” Chin J Cell Mol Immunol. 22(2) (2006) (3 pages). [cited by applicant]
Zeng et al., “Effect of overexpression of human leukocyte antigen-G in hepatocellular carcinoma Hep3B cells on killing activity of NK cells in vitro,” Chinese Journal of Pathophysiology 28(4):613-618 (2012) (6 pages). [cited by applicant]
Notice of Reasons for Rejection for Japanese Application No. 2022-505424, issued Mar. 22, 2023 (8 pages). [cited by applicant]
Allan et al., “Tetrameric complexes of HLA-E, HLA-F, and HLA-G,” J Immunol Methods. 268(1):43-50 (2002). [cited by applicant]
Almagro et al., “Humanization of antibodies,” Front Biosci. 13:1619-33 (2008). [cited by applicant]
Amiot et al., “Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?,” Cell Mol Life Sci. 68(3):417-31 (2011). [cited by applicant]
Amiot et al., “Immunomodulatory Properties of HLA-G in Infectious Diseases,” J Immunol Res. 2014:298569 (2014) (15 pages). [cited by applicant]
Amodio et al., “New insights into HLA-G mediated tolerance,” Tissue Antigens. 84(3):255-63 (2014). [cited by applicant]
Apps et al., “HLA-G is present on the surface of normal extravillous trophoblast as homodimers with high avidity for the LILR receptors of decidual leukocytes,” 4th International Conference on HLA-G, Jul. 10-12, Paris, … [cited by applicant]
Atwell et al., “Stable Heterodimers from Remodeling the Domain Interface of a Homodimer using a Phage Display Library,” J Mol Biol. 270(1):26-35 (1997). [cited by applicant]
Baca et al., “Antibody Humanization Using Monovalent Phage Display,” J Biol Chem. 272(16):10678-84 (1997) (8 pages). [cited by applicant]
Bacac et al., “CEA TCB: A novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors,” Oncoimmunology. 5(8):e1203498 (2016) (3 pages). [cited by applicant]
Bensussan et al., “Detection of membrane-bound HLA-G translated products with a specific monoclonal antibody,” Proc Natl Acad Sci U S A. 92(22):10292-6 (1995). [cited by applicant]
Boerner et al., “Production of antigen-specific human monoclonal antibodies from in vitro-primed human splenocytes,” J Immunol. 147(1):86-95 (1991). [cited by applicant]
Borges et al., “Interactions of LIRs, a Family of Immunoreceptors Expressed in Myeloid and Lymphoid Cells, with Viral and Cellular MHC Class I Antigens.” [cited by applicant]
Boyson et al., “Disulfide bond-mediated dimerization of HLA-G on the cell surface,” Proc Natl Acad Sci U S A. 99(25):16180-5 (2002). [cited by applicant]
Brennan et al., “Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G [cited by applicant]
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas,” Monoclonal Antibody Production Techniques and Applications. New York:51-63 (1987). [cited by applicant]
Brüggemann et al., “Comparison of the Effector Functions of Human Immunoglobulins Using a Matched set of Chimeric Antibodies,” J Exp Med. 166(5):1351-61 (1987). [cited by applicant]
Cantoni et al., “p49, a putative HLA class I-specific inhibitory NK receptor belonging to the immunoglobulin superfamily,” Eur J Immunol. 28(6):1980-90 (1998). [cited by applicant]
Carter, “Bispecific human IgG by design,” J Immunol Methods. 248(1-2):7-15 (2001). [cited by applicant]
Carter et al., “Humanization of an anti-p185 [cited by applicant]
Chang et al., “Tolerization of dendritic cells by Ts cells: the crucial role of inhibitory receptors ILT3 and ILT4,” Nat Immunol. 3(3):237-43 (2002). [cited by applicant]
Chari et al., “Immunoconjugates Containing Novel Maytansinoids: Promising Anticancer Drugs,” Cancer Res. 52(1):127-31 (1992). [cited by applicant]
Charlton, “Expression and Isolation of Recombinant Antibody Fragments in [cited by applicant]
Chen et al., “Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen,” J Mol Biol. 293(4):865-81 (1999). [cited by applicant]
Chowdhury, “Engineering Hot Spots for Affinity Enhancements of Antibodies,” [cited by applicant]
Clackson et al., “Making antibody fragments using phage display libraries,” Nature. 352(6336):624-8 (1991). [cited by applicant]
Clements et al., “Crystal structure of HLA-G: A nonclassical MHC class I molecule expressed at the fetal-maternal interface,” Proc Natl Acad Sci U S A. 102(9):3360-5 (2005). [cited by applicant]
Clynes et al., “Fc receptors are required in passive and active immunity to melanoma,” Proc Natl Acad Sci U S A. 95(2):652-6 (1998). [cited by applicant]
Colonna et al., “A novel family of Ig-like receptors for HLA class I molecules that modulate function of lymphoid and myeloid cells,” J Leukoc Biol. 66(3):375-81 (1999). [cited by applicant]
Cragg et al., “Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents,” Blood. 103(7):2738-43 (2004). [cited by applicant]
Cragg et al., “Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts,” Blood. 101(3):1045-52 (2003). [cited by applicant]
Cunningham et al., “High-Resolution Epitope Mapping of hGH-Receptor Interactions by Alanine-Scanning Mutagenesis,” Science. 244(4908):1081-5 (1989). [cited by applicant]
Dall'Acqua et al., “Antibody humanization by framework shuffling,” Methods. 36(1):43-60 (2005). [cited by applicant]
Ding et al., “OPL077: Experimental Study of Human Umbilical Cord Blood Cells Transplantation for Treatment of Cerebral Ischemia in rats,” Journal of the Neurological Sciences. 238:S65 (2005) (Abstract only) (1 page). [cited by applicant]
Dubowchik et al., “Doxorubicin Immunoconjugates Containing Bivalent, Lysosomally-Cleavable Dipeptide Linkages,” Bioorg Med Chem Lett. 12(11):1529-32 (2002). [cited by applicant]
Duncan et al., “The binding site for C1q on IgG,” Nature. 332(6166):738-40 (1988). [cited by applicant]
Fellouse et al., “Synthetic antibodies from a four-amino-acid code: A dominant role for tyrosine in antigen recognition,” Proc Natl Acad Sci U S A. 101(34):12467-72 (2004). [cited by applicant]
Fournel et al., “Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules,” Tissue Antigens. 55(6):510-8 (2000). [cited by applicant]
Fägerstam et al., “Detection of Antigen-Antibody Interactions by Surface Plasmon Resonance: Application to Epitope Mapping,” J Mol Recognit. 3(5-6):208-14 (1990). [cited by applicant]
Gazzano-Santoro et al., “A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody,” J Immunol Methods. 202(2):163-171 (1997). [cited by applicant]
Gerngross, “Advances in the production of human therapeutic proteins in yeasts and filamentous fungi,” Nat Biotechnol. 22(11):1409-1414 (2004). [cited by applicant]
Gonen-Gross et al., “Complexes of HLA-G Protein on the Cell Surface Are Important for Leukocyte Ig-Like Receptor-1 Function,” J Immunol. 171(3):1343-1351 (2003). [cited by applicant]
Gonen-Gross et al., “The CD85J/Leukocyte Inhibitory Receptor-1 Distinguishes between Conformed and beta2-Microglobulin-Free HLA-G Molecules,” J Immunol. 175(8):4866-74 (2005) (10 pages). [cited by applicant]
Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J Gen Virol. 36(1):59-72 (1977). [cited by applicant]
Griffiths et al., “Human anti-self antibodies with high specificity from phage display libraries,” Embo J. 12(2):725-34 (1993). [cited by applicant]
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Guyer et al., “Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors,” J Immunol. 117(2):587-593 (1976). [cited by applicant]
Hara et al., “Altered Expression of Human Leukocyte Antigen G (HLA-G) on Extravillous Trophoblasts in Preeclampsia: Immunohistological Demonstration With Anti-HLA-G Specific Antibody ‘87G’ and Anti-cytokeratin Antibody … [cited by applicant]
Hellström et al., “Antitumor effects of L6, an IgG2a antibody that reacts with most human carcinomas,” Proc Natl Acad Sci U S A. 83(18):7059-63 (1986). [cited by applicant]
Hellström et al., “Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside,” Proc Natl Acad Sci U S A. 82(5):1499-1502 (1985). [cited by applicant]
Hinman et al., “Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibodies,” Cancer Res. 53(14):3336-42 (1993). [cited by applicant]
Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments,” Proc Natl Acad Sci U S A. 90(14):6444-48 (1993). [cited by applicant]
Holliger et al., “Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody,” Protein Eng. 9(3):299-305 (1996). [cited by applicant]
Hoogenboom et al., “By-passing Immunisation. Human Antibodies from Synthetic Repertoires of Gemline V [cited by applicant]
Hoogenboom et al., “Overview of Antibody Phage-Display Technology and Its Applications,” Methods Mol Biol. 178:1-37 (2002). [cited by applicant]
Hudson et al., “Engineered antibodies,” Nat Med. 9(1):129-134 (2003). [cited by applicant]
Hunt et al., “HLA-G and immune tolerance in pregnancy,” Faseb J. 19(7):681-693 (2005). [cited by applicant]
Jeffrey et al., “Dipeptide-based highly potent doxorubicin antibody conjugates,” Bioorg Med Chem Lett. 16(2):358-362 (2006). [cited by applicant]
Johnson et al., “Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion,” J Mol Biol. 399(3):436-449 (2010). [cited by applicant]
Ju et al., “Immunoglobulin-like transcripts ILT2, ILT3 and ILT7 are expressed by human dendritic cells and down-regulated following activation,” Gene. 331:159-164 (2004). [cited by applicant]
Kam et al., “Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction,” Proc Natl Acad Sci U S A. 102(33):11600-605 (2005). [cited by applicant]
Kashmiri et al., “SDR grafting—a new approach to antibody humanization,” Methods. 36(1):25-34 (2005). [cited by applicant]
Kim et al., “Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor,” Eur J Immunol. 24(10):2429-2434 (1994). [cited by applicant]
King et al., “Monoclonal Antibody Conjugates of Doxorubicin Prepared with Branched Peptide Linkers: Inhibition of Aggregation by Methoxytriethyleneglycol Chains,” J Med Chem. 45(19):4336-43 (2002). [cited by applicant]
Kipriyanov et al., “Bispecific Tandem Diabody for Tumor Therapy with Improved Antigen Binding and Pharmacokinetics,” J Mol Biol. 293(1):41-56 (1999). [cited by applicant]
Klein et al., “The use of CrossMAb technology for the generation of bi- and multispecific antibodies,” MAbs. 8(6):1010-20 (2016). [cited by applicant]
Klimka et al., “Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning,” Br J Cancer. 83(2):252-260 (2000). [cited by applicant]
Kostelny et al., “Formation of a bispecific antibody by the use of leucine zippers,” J Immunol. 148(5):1547-1553 (1992). [cited by applicant]
Kozbor et al., “A Human Hybrid Myeloma for Production of Human Monoclonal Antibodies,” J Immunol. 133(6):3001-5 (1984). [cited by applicant]
Kratz et al., “Prodrugs of Anthracyclines in Cancer Chemotherapy,” Curr Med Chem. 13(5):477-523 (2006). [cited by applicant]
Kuroki et al., “Immune modulation of HLA-G dimer in maternal-fetal interface,” Eur J Immunol. 37(7):1727-29 (2007). [cited by applicant]
Lee et al., “Bivalent antibody phage display mimics natural immunoglobulin,” J Immunol Methods. 284(1-2):119-32 (2004). [cited by applicant]
Lee et al., “High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework Scaffold,” J Mol Biol. 340(5):1073-93 (2004). [cited by applicant]
Li et al., “Human antibodies for immunotherapy development generation via a human B cell hybridoma technology,” Proc Natl Acad Sci U S A. 103(10):3557-62 (2006). [cited by applicant]
Li et al., “Optimization of humanized IgGs in glycoengineered [cited by applicant]
Lin et al., “Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy,” Mol Med. 21(1):782-91 (2015). [cited by applicant]
Lo et al., “Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice,” J Biol Chem. 292(9):3900-3908 (2017) (10 pages). [cited by applicant]
Lode et al., “Targeted Therapy with a Novel Enediyene Antibiotic Calicheamicin theta(I) 1 Effectively Suppresses Growth and Dissemination of Liver Metastases in a Syngeneic Model of Murine Neuroblastoma,” Cancer Res. 58… [cited by applicant]
Lonberg, “Fully human antibodies from transgenic mouse and phage display platforms,” Curr Opin Immunol. 20(4):450-459 (2008). [cited by applicant]
Lonberg, “Human antibodies from transgenic animals,” Nat Biotechnol. 23(9):1117-25 (2005). [cited by applicant]
Lum et al., “Targeting T Cells with Bispecific Antibodies for Cancer Therapy,” available in PMC Oct. 8, 2013, published in final edited form as: Biodrugs. 25(6):365-379 (2011) (24 pages). [cited by applicant]
Maric et al., “Defective Antigen Processing in GILT-Free Mice,” Science. 294(5545):1361-5 (2001). [cited by applicant]
Marks et al., “By-passing Immunization Human Antibodies from V-gene Libraries Displayed on Phage,” J Mol Biol. 222(3):581-97 (1991). [cited by applicant]
Marks et al., “Selection of human antibodies from phage display libraries.” [cited by applicant]
Mather et al., “Culture of Testicular Cells in Hormone-Supplemented Serum-Free Medium,” Ann N Y Acad Sci. 383:44-68 (1982). [cited by applicant]
Mather, “Establishment and Characterization of Two Distinct Mouse Testicular Epithelial Cell Lines,” Biol Reprod. 23(1):243-252 (1980). [cited by applicant]
McCafferty et al., “Phage antibodies: filamentous phage displaying antibody variable domains,” Nature. 348(6301):552-4 (1990). [cited by applicant]
Meissner et al., “Transient Gene Expression: Recombinant Protein Production with Suspension-Adapted HEK293-EBNA Cells,” Biotechnol Bioeng. 75(2):197-203 (2001). [cited by applicant]
Menier et al., “Characterization of Monoclonal Antibodies Recognizing HLA-G or HLA-E: New Tools to Analyze the Expression of Nonclassical HLA Class I Molecules,” Hum Immunol. 64(3):315-26 (2003). [cited by applicant]
Menier et al., “MICA Triggering Signal for NK Cell Tumor Lysis is Counteracted by HLA-G1-Mediated Inhibitory Signal,” Int J Cancer. 100(1):63-70 (2002). [cited by applicant]
Milstein et al., “Hybrid hybridomas and their use in immunohistochemistry,” Nature. 305(5934):537-40 (1983). [cited by applicant]
Morrison et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” Proc Natl Acad Sci U S A. 81(21):6851-5 (1984). [cited by applicant]
Nagorsen et al., “Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab,” Exp Cell Res. 317(9):1255-60 (2011). [cited by applicant]
Nagy et al., “Stability of cytotoxic luteinizing hormone-releasing hormone conjugate (AN-152) containing doxorubicin 14-O-hemiglutarate in mouse and human serum in vitro: Implications for the design of preclinical studi… [cited by applicant]
Nakajima et al., “Transcriptional Regulation of ILT Family Receptors,” J Immunol. 171(12):6611-20 (2003). [cited by applicant]
Ni, “Research progress and future perspectives in antibodomics and antibodomic drugs,” HCAPLUS Accession No. 2006:1101736. Xiandai Mianyixue. 26(4):265-268 (2006) (Abstract Only) (3 pages). [cited by applicant]
Osbourn et al., “From rodent reagents to human therapeutics using antibody guided selection,” Methods. 36(1):61-8 (2005). [cited by applicant]
Padlan, “A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties,” Mol Immunol. 28(4-5):489-98 (1991). [cited by applicant]
Petkova et al., “Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease,” Int Immunol. 18(12):1759-69 (2006). [cited by applicant]
Pluckthun, Chapter 11: Antibodies from [cited by applicant]
Polakova et al., “Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients,” Neoplasma. 50(5):331-8 (2003). [cited by applicant]
Ponte et al., “Inhibitory receptors sensing HLA-G1 molecules in pregnancy: Decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor,” Proc Natl Acad Sci U S A. 96… [cited by applicant]
Presta et al., “Humanization of an Antibody Directed Against IgE,” J Immunol. 151(5):2623-32 (1993). [cited by applicant]
Queen et al., “A humanized antibody that binds to the interleukin 2 receptor,” Proc Natl Acad Sci U S A. 86(24):10029-33 (1989). [cited by applicant]
Rajagopalan et al., “A Human Histocompatibility Leukocyte Antigen (HLA)-G-specific Receptor Expressed on All Natural Killer Cells,” J Exp Med. 189(7):1093-99 (1999). [cited by applicant]
Ridgway et al., “Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Eng. 9(7):617-21 (1996). [cited by applicant]
Riechmann et al., “Reshaping human antibodies for therapy,” Nature. 322(6162):323-7 (1988). [cited by applicant]
Ristich et al., “Tolerization of dendritic cells by HLA-G,” Eur J Immunol. 35(4):1133-42 (2005). [cited by applicant]
Riteau et al., “HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition,” Int Immunol. 13(2):193-201 (2001). [cited by applicant]
Roosnek et al., “T cell activation by a bispecific anti-CD3/anti-major histocompatibility complex class I antibody,” Eur J Immunol. 20(6):1393-6 (1990). [cited by applicant]
Rosok et al., “A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab,” J Biol Chem. 271(37):22611-8 (1996). [cited by applicant]
Ruan et al., “Recent progress of HLA-G in cancer,” Chinese Bulletin of Life Sciences. 24(3):242-49 (2012) (English language abstract). [cited by applicant]
Rudolph et al., “Crystal Structures of Two Rat MHC Class Ia (RT1-A) Molecules that are Associated Differentially with Peptide Transporter Alleles TAP-A and TAP-B,” J Mol Biol. 324(5):975-90 (2002). [cited by applicant]
Sanders et al., “Cell-Cell Adhesion Mediated by CD8 and Human Histocompatibility Leukocyte Antigen G, a Nonclassical Major Histocompatibility Complex Class 1 Molecule on Cytotrophoblasts,” J Exp Med. 174(3):737-40 (1991… [cited by applicant]
Schaefer et al., “Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies,” Proc Natl Acad Sci U S A. 108(27):11187-92 (2011). [cited by applicant]
Seimetz et al., “Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy,” Cancer Treat Rev. 36(6):458-67 (2010). [cited by applicant]
Selvakumar et al., “NK cell receptor gene of the KIR family with two IG domains but highest homology to KIR receptors with three IG domains,” Tissue Antigens. 48(4 Pt 1):285-94 (1996). [cited by applicant]
Sheu et al., “HLA-G and Immune Evasion in Cancer Cells,” J Formos Med Assoc. 109(4):248-57 (2010). [cited by applicant]
Shields et al., “High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR,” J Biol Chem. 276(9):6591-604 (2001). [cited by applicant]
Shiroishi et al., “Efficient Leukocyte Ig-like Receptor Signaling and Crystal Structure of Disulfide-linked HLA-G Dimer,” The Journal of Biological Chemistry. 281(15):10439-47 (2006) (10 pages). [cited by applicant]
Shiroishi et al., “Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G,” Proc Natl Acad Sci U S A. 100(15):8856-61 (2003). [cited by applicant]
Shore et al., “Chain B, YTS 105.18 Antigen Binding Region Heavy Chain,” GenBank, accession No. 2ARJ_B (2020) (3 pages). [cited by applicant]
Sidhu et al., “Phage-displayed Antibody Libraries of Synthetic Heavy Chain Complementarity Determining Regions,” J Mol Biol. 338(2):299-310 (2004). [cited by applicant]
Sims et al., “A Humanized CD18 Antibody Can Block Function without Cell Destruction,” J Immunol. 151(4):2296-308 (1993). [cited by applicant]
Spiess et al., “Alternative molecular formats and therapeutic applications for bispecific antibodies,” Mol Immunol. 67(2 Pt A):95-106 (2015). [cited by applicant]
Spurny et al., “T cell infiltration into Ewing sarcomas is associated with local expression of immune-inhibitory HLA-G,” Oncotarget. 9(5):6536-49 (Dec. 22, 2017). [cited by applicant]
Stoel et al., “Immunoglobulin heavy chain variable region, partial [Rattus norvegicus],” GenBank, accession No. CAL25600 (2016) (2 pages). [cited by applicant]
Suciu-Foca et al., “Molecular characterization of allospecific T suppressor and tolerogenic dendritic cells: review,” Int Immunopharmacol. 5(1):7-11 (2005). [cited by applicant]
Torgov et al., “Generation of an Intensely Potent Anthracycline by a Monoclonal Anitbody-Beta-Galactosidase Conjugate,” Bioconjug Chem. 16(3):717-21 (2005). [cited by applicant]
Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,” EMBO J. 10(12):3655-9 (1991). [cited by applicant]
Tutt et al., “Trispecific F(ab') [cited by applicant]
Urlaub et al., “Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity,” Proc Natl Acad Sci U S A. 77(7):4216-20 (1980). [cited by applicant]
Valiante et al., “Functionally and Structurally Distinct NK Cell Receptor Repertoires in the Peripheral Blood of Two Human Donors,” Immunity. 7(6):739-51 (1997). [cited by applicant]
Valliere-Douglass et al., “Glutamine-linked and Non-consensus Asparagine-linked Oligosaccharides Present in Human Recombinant Antibodies Define Novel Protein Glycosylation Motifs,” J Biol Chem. 285(21):16012-22 (2010). [cited by applicant]
Van de Bovenkamp et al., “Adaptive antibody diversification through N-linked glycosylation of the immunoglobulin variable region,” Proc Natl Acad Sci U S A. 115(8):1901-1906 (Feb. 20, 2018). [cited by applicant]
Van Dijk et al., “Human antibodies as next generation therapeutics,” Curr Opin Chem Biol. 5(4):368-74 (2001). [cited by applicant]
Vitetta et al., “Redesigning Nature's Poisons to Create Anti-Tumor Reagents,” Science. 238(4830):1098-104 (1987). [cited by applicant]
Vollmers et al., “Death by Stress: Natural IgM-Induced Apoptosis,” Methods Find Exp Clin Pharmacol. 27(3):185-91 (2005). [cited by applicant]
Vollmers et al., “The ‘early birds’: natural IgM antibodies and immune surveillance,” Histol Histopathol. 20(3):927-37 (2005). [cited by applicant]
Wan et al., “Human Leukocyte Antigen-G Inhibits the Anti-Tumor Effect of Natural Killer Cells via Immunoglobulin-Like Transcript 2 in Gastric Cancer,” Cell Physiol and Biochem. 44(5):1828-41 (2017). [cited by applicant]
Wiendl et al., “The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy,” Brain. 126(Pt. 1):176-85 (2003). [cited by applicant]
Winter et al., “Making Antibodies by Phage Display Technology,” Annu Rev Immunol. 12:433-55 (1994). [cited by applicant]
Wu et al., “Rescuing lymphocytes from HLA-G immunosuppressive effects mediated by the tumor microenvironment,” Oncotarget. 6(35):37385-97 (2015). [cited by applicant]
Yazaki et al., “Expression of Recombinant Antibodies in Mammalian Cell Lines.” [cited by applicant]
Extended European Search Report for European Patent Application No. 20214951.4, dated Jul. 20, 2021 (13 pages). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/EP2017/079429, mailed May 31, 2019 (9 pages). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2019/060007, mailed Oct. 29, 2020 (11 pages). [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/EP2019/060008, issued Oct. 20, 2020 (7 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2017/079429, mailed Mar. 20, 2018 (13 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/060007, mailed Jul. 17, 2019 (19 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2019/060008, mailed May 27, 2019 (12 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/EP2021/085810, mailed Apr. 7, 2022 (20 pages). [cited by applicant]
Invitation to Respond to Written Opinion for Singaporean Application No. 11202009695Q, dated Apr. 27, 2022 (12 pages). [cited by applicant]
Roitt et al., “Different antigen antibody binding is ensured by hypervariable sequences of antigen-recognizing centers,” Moscow, Mir: Immunology. 110-1 (2000) (5 pages). [cited by applicant]
Singer et al., “Genes and Genomes,” Moskow “MIR”. 1:63-64 (1998) (7 pages). [cited by applicant]
Kuznetzova, E. A., “Brackets in text of legal document as a linguistic and cognitive phenomenon,” Vestnik MGOU. Series: Russian Philology. 3:37-42 (2015) (12 pages). [cited by applicant]
Office Action for Russian Patent Application No. 2020 137 068, dated Oct. 5, 2022 (16 pages). [cited by applicant]
U.S. Appl. No. 18/446,032, Hoffmann-La Roche Inc. [cited by applicant]
“Annex 4-15E7 Specificity and Blocking Activity,” experimental annex cited in opposition to patent EP2917229B1 on Oct. 6, 2020, by Regimbeau (5 pages). [cited by applicant]
“Immunologists' Toolbox: Immunization.” Excerpt from Janeway's Immunobiology, eds. Murphy et al., 7th ed., p. 735 (2008) (3 pages). [cited by applicant]
Abcam Product Datasheet for “Anti-HLA G antibody [MEM-G/1] ab7759” cited in opposition to patent EP2917229B1 on Oct. 7, 2020 (3 pages). [cited by applicant]
Agaugué et al., “Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinic balance in favor of Th2 versus Th1/Th17,” Blood. 117(26):7021-31 (Jun. 30, 2011). [cited by applicant]
Angal et al., “A single amino acid substitution abolishes the heterogeneity of chimeric mouse/human (IgG4) antibody,” Mol Immunol. 30(1):105-8(1993). [cited by applicant]
Apps et al., “A critical look at HLA-G,” Trends Immunol. 29(7):313-21 (2008). [cited by applicant]
Arns et al., “Structural Modeling and Molecular Dynamics of the Immune Checkpoint Molecule HLA-G,” Front. Immunol. 11:575076. doi: 10.3389/fimmu.2020.575076 (Nov. 2020). [cited by applicant]
Barnstable et al., “Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis,” Cell 14(1) Abstract (1978). [cited by applicant]
Barnstable et al., “Production of Monoclonal Antibodies to Group A Erythrocytes, HLA and Other Human Cell Surface Antigens—New Tools for Genetic Analysis,” Cell. 14(1):9-20 (1978). [cited by applicant]
Beers et al., “Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation,” Blood 112(10):4170-4177 (2008). [cited by applicant]
Blaschitz et al., “The soluble pool of HLA-G produced by human trophoblasts does not include detectable levels of the intron 4-containing HLA-G5 and HLA-G6 isoforms,” Molecular Human Reproduction 11(10):699-710 (2005). [cited by applicant]
Carosella et al., “Beyond the increasing complexity of the immunomodulatory HLA-G molecule,” Blood. 111(10):4862-70 (May 15, 2008). [cited by applicant]
Carosella et al., “HLA-G: from biology to clinical benefits,” Trends in Immunology. 29(3):125-32 (2008). [cited by applicant]
Chaplin, David D., “Overview of the immune response,” J Allergy Clin Immunol. 125(2 Suppl 2):S3-23 (2010). [cited by applicant]
Chua et al., “Chapter 40: Production of Monoclonal Antibody by DNA Immunization with Electroporation,” S. Li (ed.), Electroporation Protocols: Preclinical and Clinical Gene Medicine. From Methods in Molecular Biology. 4… [cited by applicant]
Contini et al., “Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8 [cited by applicant]
Deng et al., “Enhancing antibody patent protection using epitope mapping information,” MABS 10(2):204-209 (2018) (published online: Dec. 7, 2017). [cited by applicant]
Desai et al., “Structural Relatedness of Distinct Determinants Recognized by Monoclonal Antibody TP25.99 on beta [cited by applicant]
Diaz-Lagares et al., “Nitric oxide produces HLA-G nitration and induces metalloprotease-dependent shedding creating a tolerogenic milieu,” Immunology. 126(3):436-45 (2008). [cited by applicant]
Donadi et al., “Implications of the polymorphism of HLA-G on its function, regulation, evolution and disease association,” Cell Mol Life Sci. 68:369-95 (2011). [cited by applicant]
Fioretti et al., “DNA Vaccines: Developing New Strategies against Cancer,” J Biomed Biotechnol. 2010:174378 (2010) (16 pages). [cited by applicant]
Furukawa et al., “Evaluation of the Reactivity and Receptor Competition of HLA-G Isoforms toward Available Antibodies: Implications of Structural Characteristics of HLA-G Isoforms,” Int J Mol Sci. 20:5947 (Nov. 26, 2019… [cited by applicant]
Gauster et al., “Monoclonal antibody HC10 does not bind HLA-G,” Rheumatology. 46:892-3 (2007). [cited by applicant]
Geraghty et al., “A human major histocompatibility complex class I gene that encodes a protein with a shortened cytoplasmic segment,” Proc Natl Acad Sci USA. 84(1):9145-9 (Dec. 1987). [cited by applicant]
Ishitani et al., “Protein Expression and Peptide Binding Suggest Unique and Interacting Functional Roles for HLA-E, F, and G in Maternal-Placental Immune Recognition,” J Immunol. 171(3):1376-84 (2003). [cited by applicant]
Kobayashi et al., “Establishment of a Choriocarcinoma Model from Immortalized Normal Extravillous Trophoblast Cells Transduced with HRASV12,” Am J Pathol. 179(3):1471-82 (2011). [cited by applicant]
Kovats et al., “A Class I Antigen, HLA-G, Expressed in Human Trophoblasts,” Science 248:220-223 (1990). [cited by applicant]
Kutzler et al., “DNA vaccines: ready for prime time?” Nat Rev Genet. 9(10):776-88 (2008). [cited by applicant]
Laddy et al., “From Plasmids to Protection: A Review of DNA Vaccines Against Infectious Diseases,” International Reviews of Immunology. 25:99-123 (2006) (26 pages). [cited by applicant]
Le Discorde et al., “HLA-G*0105N Null Allele Encodes Functional HLA-G Isoforms,” Biol Reprod. 73(2):280-8 (2005). [cited by applicant]
Le Gal et al., “HLA-G-mediated inhibition of antigen-specific cytotoxic T lymphocytes,” International Immunology. 11(8):1351-6 (1999). [cited by applicant]
Le Rond et al., “Alloreactive CD4 [cited by applicant]
Lee et al., “The Membrane-Bound and Soluble Forms of HLA-G Bind Identical Sets of Endogenous Peptides but Differ with Respect to TAP Association,” Immunity. 3:591-600 (1995). [cited by applicant]
Liang et al., “HLA-G inhibits the functoins of murine dendritic cells via the PIR-B immune inhibitory receptor,” Eur J Immunol. 32:2418-26 (2002). [cited by applicant]
Lin et al., “HLA-G expression in human ovarian carcinoma counteracts NK cell function,” Annals of Oncology. 18(11):1804-9 (2007). [cited by applicant]
Loke et al., “Evaluation of trophoblast HLA-G antigen with a specific monoclonal antibody,” Tissue Antigens. 50:135-46 (1997). [cited by applicant]
Loumagne et al., “In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance,” Int J Cancer. 135:2107-17 (2014). [cited by applicant]
Loustau et al., “HLA-G Neo-Expression on Tumors,” Frontiers in Immunology. 11(1685) (Aug. 14, 2020) (15 pages). [cited by applicant]
Cited By (1)
US 12,715,923